1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Norway Pharmaceuticals and Healthcare Report Q4 2016

Norway Pharmaceuticals and Healthcare Report Q4 2016

  • October 2016
  • -
  • Business Monitor International
  • -
  • 64 pages

Includes 3 FREE quarterly updates

BMI View:

As Norway's economy continues to rebalance away from oil dependence, industrial policy aimed at boosting production capacity and research in the health sector is set to strengthen. In fact, Norway's government has identified the life sciences and biomedical sector as a priority area in terms of its long-term growth strategy, suggesting that we will see further policy developments to attract investment in the sector over the coming years. Meanwhile, we expect demand-side market growth drivers, such as ageing and high spending per capita on healthcare, to translate to sustained pharmaceutical market growth over the forecast period.

Headline Expenditure Projections
Pharmaceuticals: NOK23.40bn (USD2.78bn) in 2015 to NOK23.71bn (USD2.70bn) in 2016; +1.3% in local currency terms and -2.6% in US dollar terms. Forecast revised upwards in local currency terms and slightly downwards in US dollar terms from last quarter. Healthcare: NOK316.68bn (USD37.56bn) in 2015 to NOK327.80bn (USD37.39bn) in 2016; +3.5% in local currency terms and +0.5% in US dollar terms. Forecast broadly in line in local currency terms and revised downwards in US dollar terms from last quarter.

Table Of Contents

Norway Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Norway 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Norway 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Norway 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Norway 2012-2020) 22
Pharmaceutical Trade Forecast 23
Table: Pharmaceutical Trade Data And Forecasts (Norway 2014-2020) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (Norway 2014-2020) 25
Industry Risk/Reward Index 26
Western Europe Risk/Reward Index 26
Norway Risk/Reward Index 32
Rewards 32
Risks 32
Regulatory Review 34
Pricing Regime 36
Reimbursement Regime 38
Market Overview 40
Healthcare Sector 41
Table: Healthcare Resources (Norway 2010-2015) 42
Table: Healthcare Personnel (Norway 2010-2015) 42
Table: Healthcare Activity (Norway 2010-2015) 43
Research And Development 43
Clinical Trials 45
Epidemiology 46
Competitive Landscape 48
Table: The Top 25 Pharmaceutical Companies In Norway 49
Table: Multinational Market Activity 51
Demographic Forecast 53
Table: Population Headline Indicators (Norway 1990-2025) 54
Table: Key Population Ratios (Norway 1990-2025) 54
Table: Urban/Rural Population and Life Expectancy (Norway 1990-2025) 55
Table: Population By Age Group (Norway 1990-2025) 55
Table: Population By Age Group % (Norway 1990-2025) 56
Glossary 58
Methodology 60
Pharmaceutical Expenditure Forecast Model 60
Healthcare Expenditure Forecast Model 60
Notes On Methodology 61
Risk/Reward Index Methodology 62
Index Overview 63
Table: Pharmaceutical Risk/Reward Index Indicators 63
Indicator Weightings 64

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.